Payment overview · 2025
General Payments
$125.00
1 reported records · 1 companies
Healthcare provider profile · identity verified
Terry K Brooks, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LANOKA HARBOR, NJ · NPI 1013257740
Verified facts
What the public records show
CMS Open Payments records show Terry K Brooks, NP-C received $125.00 in general payments during 2025 across 1 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $125.00 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $125.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 406 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 361 | 61 |
| Furosemide | Furosemide | 328 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 303 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 254 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 246 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 221 | 41 |
| Eliquis | Apixaban | 220 | 44 |
| Gabapentin | Gabapentin | 205 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 34 |
| Divalproex Sodium | Divalproex Sodium | 174 | 34 |
| Potassium Chloride | Potassium Chloride | 169 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 35 |
| Alprazolam | Alprazolam | 166 | 41 |
| Trazodone Hcl | Trazodone Hcl | 159 | 38 |
| Omeprazole | Omeprazole | 153 | 31 |
| Losartan Potassium | Losartan Potassium | 134 | 26 |
| Tramadol Hcl | Tramadol Hcl | 133 | 39 |
| Valsartan | Valsartan | 128 | 20 |
| Donepezil Hcl | Donepezil Hcl | 126 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 122 | 26 |
| Lisinopril | Lisinopril | 118 | 22 |
| Baclofen | Baclofen | 107 | 13 |
| Mirtazapine | Mirtazapine | 107 | 22 |
| Famotidine | Famotidine | 105 | 18 |
| Levetiracetam | Levetiracetam | 103 | 13 |
| Finasteride | Finasteride | 96 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 24 |
| Simvastatin | Simvastatin | 93 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 13 |
| Clonazepam | Clonazepam | 89 | 12 |
| Sertraline Hcl | Sertraline Hcl | 87 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 84 | 11 |
| Spironolactone | Spironolactone | 83 | 13 |
| Prednisone | Prednisone | 78 | 25 |
| Carvedilol | Carvedilol | 75 | 13 |
| Allopurinol | Allopurinol | 74 | 16 |
| Torsemide | Torsemide | 72 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 65 | suppressed |
| Lorazepam | Lorazepam | 64 | 32 |
| Metformin Hcl | Metformin Hcl | 63 | suppressed |
| Nystatin | Nystatin | 62 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | suppressed |
| Latanoprost | Latanoprost | 59 | suppressed |
| Bupropion Xl | Bupropion Hcl | 57 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 55 | 11 |
| Buspirone Hcl | Buspirone Hcl | 54 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | suppressed |
| Risperidone | Risperidone | 52 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 40 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 48 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 48 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 47 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 12 |
| Sucralfate | Sucralfate | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 11 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Celecoxib | Celecoxib | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 12 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Ketoconazole | Ketoconazole | 42 | 11 |
| Lansoprazole | Lansoprazole | 41 | suppressed |
| Glipizide Er | Glipizide | 40 | suppressed |
| Olanzapine | Olanzapine | 40 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Meloxicam | Meloxicam | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 25 |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 27 |
| Folic Acid | Folic Acid | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Nystop | Nystatin | 29 | 15 |
| Lidocaine | Lidocaine | 28 | suppressed |
| Lumigan | Bimatoprost | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 20 |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 18 | 16 |
| Glimepiride | Glimepiride | 18 | suppressed |
| Klor-Con 10 | Potassium Chloride | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 15 |
| Pregabalin | Pregabalin | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Entacapone | Entacapone | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Xtampza Er | Oxycodone Myristate | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cetirizine Hcl | Cetirizine Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 13 | suppressed |
| Nayzilam | Midazolam | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Alphagan P | Brimonidine Tartrate | 11 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Cozaar | Losartan Potassium | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $125.00 · 1 records | Otsuka America Pharmaceutical, Inc. | REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error